Novo Nordisk shares cratered 15% on Monday after the Danish pharma giant admitted its much-hyped weight loss drug CagriSema couldn't match Eli Lilly's blockbuster tirzepatide in head-to-head trials. For a company that rode the obesity drug boom to become Europe's most valuable corporation, this is more than a stumble—it's a reality check on what Wall Street was pricing in.

Here's what actually happened. In the REDEFINE 4 trial, CagriSema delivered 23% weight loss after 84 weeks of treatment. That sounds impressive until you realize Eli Lilly's tirzepatide hit 25.5% in the same study. In clinical trial terms, CagriSema "failed to demonstrate non-inferiority"—which is medical researcher speak for "we lost."

This matters because the obesity drug market is shaping up to be one of the most lucrative pharmaceutical categories in history. Analysts estimate it could hit $100 billion annually by 2030. Novo dominated the early innings with Wegovy and Ozempic, both powered by semaglutide. CagriSema was supposed to be the next generation—a combo drug adding amylin to the existing GLP-1 formula to squeeze out even more weight loss.

The problem? Eli Lilly already has that better drug on the market. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, works differently but delivers superior results. And Lilly isn't standing still—they've got retatrutide in late-stage trials showing even better outcomes.

For investors, this is a competitive positioning story. Novo is still profitable, still growing, and still has Wegovy flying off shelves. But the premium valuation was built on the assumption that Novo would stay ahead in the obesity arms race. Today's results suggest they're playing catch-up instead.

Martin Holst Lange, Novo's chief scientific officer, tried to spin it positively, noting they're "pleased with the weight loss of 23%" and emphasizing CagriSema would be the first GLP-1/amylin combo if approved. That's true. It's also the kind of statement you make when Plan A didn't work out.

The FDA decision is expected by late 2026, and Novo has higher-dose combinations in the pipeline. Maybe those work better. But here's the thing Wall Street doesn't like: . Novo just went from to in the space of one trial readout.